Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Real-world analysis: molecular monitoring and adherence patterns to TKIs in older patients with CML

Rory Shallis, MD, Yale Cancer Center, West Haven, CT, discusses a study which aimed to evaluate the level of appropriate molecular monitoring and adherence patterns in patients with chronic myeloid leukemia (CML) treated with tyroskine kinase inhibitors (TKIs). First, Dr Shallis gives some background information for the basis of the study, explaining that there is a percentage of patients who do not receive appropriate molecular monitoring in their first year of TKI therapy, which is crucial when analyzing whether the therapy is effective or not. Following this, Dr Shallis discusses the methodology of the study, which used the Surveillance, Epidemiology, and End Results (SEER) – Medicare database to assemble a cohort of older CML patients. Dr Shallis then explains the results from multivariable analyses that were conducted to better understand which factors influenced optimal monitoring and how the proportion of days covered (PDC) changed over time. To conclude, Dr Shallis then explains which factors influenced TKI monitoring, including socioeconomic status, time-period of diagnosis, influenza vaccination, and further emphasizes the importance of following up on treatment adherence and monitoring of patients in other studies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.